Therapy-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer.

Pamela Maxwell, David Waugh, Melissa LaBonte Wilson*

*Corresponding author for this work

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Publication statusPublished - 28 Nov 2017
Event1st European Alliance for Personalised Medicine Congress 2017 - Belfast, United Kingdom
Duration: 25 Nov 201730 Nov 2017

Conference

Conference1st European Alliance for Personalised Medicine Congress 2017
Country/TerritoryUnited Kingdom
CityBelfast
Period25/11/201730/11/2017

Cite this